- Home
- About
- PsychU For You
- Topics
- Mental Health Disorders
- Agitation
- Bipolar Disorder
- Depression
- Pseudobulbar Affect (PBA)
- PTSD/Trauma
- Schizophrenia
- Substance Use Disorders
- Topics of Interest
- Care Coordination
- Digital Health
- Diversity, Equity, & Inclusion
- Health Care Policy, Quality & Payer Administration
- Long-Term Care
- Stigma
- Suicide Awareness
- Wellness
- Events
- Content
- Supporting Organizations
Conversations Matter: The Importance Of Effective Communication Between Healthcare Providers & Care Partners Of Individuals Living With Agitation In Alzheimer’s Dementia (AAD)

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:
About This Event
Conversations Matter: The Importance Of Effective Communication Between Healthcare Providers & Care Partners Of Individuals Living With Agitation In Alzheimer’s Dementia (AAD)
Care partners play an integral role in the detection and assessment of agitation symptoms in patients with Alzheimer’s dementia1 and are often the first to communicate these behaviors to healthcare providers (HCPs)2,3. Early identification, management and treatment of AAD has been shown to improve patient outcomes and reduce caregiver burden4,5, highlighting the importance of a strong therapeutic alliance between care partners and HCPs. In this webinar, geriatric psychiatrist, Dr. Marc Agronin, and care partner, Carrie Shaw, share their unique but complimentary perspectives on identifying and responding to agitation and navigating the shared decision-making process. Our speakers will discuss best practices for how to effectively prepare for and communicate during an appointment and what tools and resources are available for care partners. One such tool they review is the AASC™, a brief screening tool based on the International Psychogeriatric Association (IPA) consensus definition for agitation in cognitive disorders6, which was designed to assist caregivers in recognizing AAD.
Click here to register for the 3:00 pm EST broadcast
References:
- Stella F, et al. Int J Geriatr Psychiatry. 2015;30(12):1230-1237
- Lindeza P, et al. BMJ Support Palliat Care. 2020; bmjspcare-2020-002242.
- Gallego-Alberto L, et al. Clin Gerontol. 2022;45(5):1295-1303.
- Hoe J, et al. BJPsych Open. 2017;3(1):34-40.
- Janzen S, et al. Am J Alzheimers Dis Other Demen. 2013;28(5):524-532
- Sano M, et al. International Psychogeriatrics 2023 :1-13. doi10.1017/S1041610222001041

Marc E. Agronin, MD
Agitation Section Advisor; President of the American Association for Geriatric Psychiatry (AAGP); Senior Vice President for Behavioral Health and Chief Medical Office for the Memory and Research Center at MIND Institute; Affiliate Associate Professor of Psychiatry and Neurology at the University of Miami Miller School of Medicine

Carrie Shaw, MD
CEO & Founder of Embodied Labs

Miranda Fisher, PhD
Medical Science Liaison
Marc Agronin and Carrie Shaw are paid consultants of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)
Miranda Fisher, PhD is a paid employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)